16
2020-10
On 16 October 2020, Kintor Pharmaceutical Limited (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (“Pumis”).
30
2020-09
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex
On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.
17
2020-09
Acne Drug KX-826 Gel Approved for Clinical Trials in China
On 17 September 2020, Kintor Pharmaceutical Limited is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.
14
2020-09
Kintor Pharma to Apply to Launch its Prostate Cancer Drug Next Season
In an interview with the Hong Kong Economic Journal, Kintor Pharmaceutical's (09939) Chief Financial Officer Lu Yan noted that the company will submit its new drug application (NDA) for its core product GT0918 for the treatment of prostate cancer next season.
11
2020-09
Among them, Kintor Pharmaceutical Limited was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020".
02
2020-09
China’s New Drugs on Way to Treating Male Baldness
According to the Insight database, KX-826, a drug of Chinese drugmaker Kintor Pharmaceutical currently in phase II clinical phase, has also been developed for the treatment of AGA.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn